PBMs’ Role in 340B Program Comes Under Microscope

  • May 22, 2025

    Amid policymakers’ ongoing scrutiny of the PBM industry, an April report from a key Senate committee likely added more fuel to the criticism by highlighting how vertically integrated health care giants like CVS Health Corp. reap increasing profits from the 340B Drug Pricing Program.  

    Further complicating matters, a new court ruling thwarts — at least temporarily — a rebate model created by drugmakers that one expert says could have added much-needed transparency to PBMs’ role in 340B. 

    Read more
    © 2025 MMIT
  • Leslie Small

    Leslie has been working in journalism since 2009 and reporting on the health care industry since 2014. She has covered the many ups and downs of the Affordable Care Act exchanges, the failed health insurer mega-mergers, and hundreds of other storylines spanning subjects such as Medicaid managed care, Medicare Advantage, employer-sponsored insurance, and prescription drug coverage. As the managing editor of Health Plan Weekly and Radar on Drug Benefits, she writes and edits for both publications while overseeing a small team of reporters who also focus on the managed care sector. Before joining AIS Health, she was a senior editor for the e-newsletter Fierce Health Payer, and she started her career as a copy editor at multiple local newspapers. She graduated with a dual degree in journalism and political science from Penn State University.

The Latest
Meet Our Reporters

Meet Our Reporters

×